Search
Zevra Therapeutics Inc
ZVRAAdd to Watchlist
12.140USD
+0.550+4.75%
Close 11-09 16:00（ET）
720.87MMarket Cap
5.75P/E TTM
Zevra Therapeutics Inc (ZVRA) Stock Price Target & Forecast
Analyst Rating
Based on 9 analysts giving stock ratings to Zevra Therapeutics Inc in the past month.
Buy
3 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
25.250USD+145.62%
ZVRA Analyst Recommendation Trends
In the current month, ZVRA has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ZVRA average Analyst price target in the last month is 25.250.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
3
3
3
3
3
3
3
2
6
6
6
6
6
6
6
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
9
9
9
9
9
9
8
ZVRA Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
9
19
3
1
36
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Eli Lilly and Co
LLY
10
19
3
1
0
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Merck & Co Inc
MRK
7
16
8
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Financial Forecasting
Based on analysts' estimates, ZVRA EPS is projected to reach 0.186 in FY2026Q4, following reported EPS of 0.323 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
0.08
0.11
0.16
0.19
0.23
Actual
0.65
0.14
0.32
--
--
Surprise
+703.08%
+32.19%
+106.38%
--
--
FAQs
What is Zevra Therapeutics Inc's expected revenue for the next quarter?
Zevra Therapeutics Inc's expected revenue is 40.09M.
What is Zevra Therapeutics Inc's price target?
Analysts forecast that Zevra Therapeutics Inc's price target is USD 25.25, with the highest forecast at USD 35.00 and the lowest forecast at USD 20.00.
How have Zevra Therapeutics IncZVRA's recent earnings per share performed?
The market expectation was USD 0.32, while Zevra Therapeutics IncZVRA's earnings per share (EPS) for the previous quarter was USD 0.14. EPS for the next quarter is expected at USD 0.19.
What is the analyst rating for Zevra Therapeutics Inc?
Based on the ratings of Zevra Therapeutics Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.